AZN » Topics » EXCHANGE RATES

This excerpt taken from the AZN 20-F filed Mar 12, 2008.
EXCHANGE RATES
For the periods up to April 1999, Astra accounted for and reported its results in Swedish kronor, whereas Zeneca accounted for and reported its results in sterling. Consistent with AstraZeneca’s decision to publish its Financial Statements in US dollars, the financial information in this document has been translated from kronor and sterling into US dollars at the following applicable exchange rates:

    SEK/USD   USD/GBP  






Average rates (profit and loss account, cash flow)          
1995   7.1100   1.5796  






1996   6.7000   1.5525  






1997   7.6225   1.6386  






1998   7.9384   1.6603  






1999   8.2189   1.6247  






           
End of year spot rates (balance sheet)          
1995   6.6500   1.5500  






1996   6.8400   1.6900  






1997   7.8500   1.6600  






1998   8.0400   1.6600  






1999   8.5130   1.6185  






The following information relating to average and spot exchange rates used by AstraZeneca is provided for convenience:

    SEK/USD   USD/GBP  






Average rates (income statement, cash flow)          
2005   7.3878   1.8306  






2006   7.4472   1.8265  






2007   6.7692   2.0003  






           
End of year spot rates (balance sheet)          
2005   7.9464   1.7239  






2006   6.8824   1.9626  






2007   6.4051   1.9932  







Back to Contents

   
  ADDITIONAL INFORMATION
192 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007

SHAREHOLDER INFORMATION CONTINUED

 

This excerpt taken from the AZN 6-K filed Mar 7, 2008.
EXCHANGE RATES
For the periods up to April 1999, Astra accounted for and reported its results in Swedish kronor, whereas Zeneca accounted for and reported its results in sterling. Consistent with AstraZeneca’s decision to publish its Financial Statements in US dollars, the financial information in this document has been translated from kronor and sterling into US dollars at the following applicable exchange rates:

    SEK/USD   USD/GBP  






Average rates (profit and loss account, cash flow)          
1995   7.1100   1.5796  






1996   6.7000   1.5525  






1997   7.6225   1.6386  






1998   7.9384   1.6603  






1999   8.2189   1.6247  






           
End of year spot rates (balance sheet)          
1995   6.6500   1.5500  






1996   6.8400   1.6900  






1997   7.8500   1.6600  






1998   8.0400   1.6600  






1999   8.5130   1.6185  






The following information relating to average and spot exchange rates used by AstraZeneca is provided for convenience:

    SEK/USD   USD/GBP  






Average rates (income statement, cash flow)          
2005   7.3878   1.8306  






2006   7.4472   1.8265  






2007   6.7692   2.0003  






           
End of year spot rates (balance sheet)          
2005   7.9464   1.7239  






2006   6.8824   1.9626  






2007   6.4051   1.9932  







Back to Contents

   
  ADDITIONAL INFORMATION
192 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007

SHAREHOLDER INFORMATION CONTINUED

 

This excerpt taken from the AZN 20-F filed Mar 27, 2007.
EXCHANGE RATES
For the periods up to April 1999, Astra accounted for and reported its results in Swedish kronor, whereas Zeneca accounted for and reported its results in sterling. Consistent with AstraZeneca’s decision to publish its Financial Statements in US dollars, the financial information in this document has been translated from kronor and sterling into US dollars at the following applicable exchange rates:

  SEK/USD   USD/GBP  




 
Average rates (profit and loss account, cash flow)        
1995 7.1100   1.5796  




 
1996 6.7000   1.5525  




 
1997 7.6225   1.6386  




 
1998 7.9384   1.6603  




 
1999 8.2189   1.6247  




 
         
End of year spot rates (balance sheet)        
1995 6.6500   1.5500  




 
1996 6.8400   1.6900  




 
1997 7.8500   1.6600  




 
1998 8.0400   1.6600  




 
1999 8.5130   1.6185  




 

The following information relating to average and spot exchange rates used by AstraZeneca is provided for convenience:

  SEK/USD   USD/GBP  




 
Average rates (income statement, cash flow)        
2004 7.4613   1.8031  




 
2005 7.3878   1.8306  




 
2006 7.4472   1.8265  




 
         
End of year spot rates (balance sheet)        
2004 6.6144   1.9264  




 
2005 7.9464   1.7239  




 
2006 6.8824   1.9626  




 

Back to Contents

SHAREHOLDER INFORMATION 171

 

This excerpt taken from the AZN 6-K filed Mar 6, 2007.
EXCHANGE RATES
For the periods up to April 1999, Astra accounted for and reported its results in Swedish kronor, whereas Zeneca accounted for and reported its results in sterling. Consistent with AstraZeneca’s decision to publish its Financial Statements in US dollars, the financial information in this document has been translated from kronor and sterling into US dollars at the following applicable exchange rates:

  SEK/USD   USD/GBP  




 
Average rates (profit and loss account, cash flow)        
1995 7.1100   1.5796  




 
1996 6.7000   1.5525  




 
1997 7.6225   1.6386  




 
1998 7.9384   1.6603  




 
1999 8.2189   1.6247  




 
         
End of year spot rates (balance sheet)        
1995 6.6500   1.5500  




 
1996 6.8400   1.6900  




 
1997 7.8500   1.6600  




 
1998 8.0400   1.6600  




 
1999 8.5130   1.6185  




 

The following information relating to average and spot exchange rates used by AstraZeneca is provided for convenience:

  SEK/USD   USD/GBP  




 
Average rates (income statement, cash flow)        
2004 7.4613   1.8031  




 
2005 7.3878   1.8306  




 
2006 7.4472   1.8265  




 
         
End of year spot rates (balance sheet)        
2004 6.6144   1.9264  




 
2005 7.9464   1.7239  




 
2006 6.8824   1.9626  




 

Back to Contents

SHAREHOLDER INFORMATION 171

 

"EXCHANGE RATES" elsewhere:

GlaxoSmithKline (GSK)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki